Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Sequentially Adaptive, Open Label, Dose-finding, Phase I/II Trial of Pentostatin in the Treatment of Steroid-refractory Acute Graft Versus Host Disease (aGvHD)

NCT00032773 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00032773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00032773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Sequentially Adaptive, Open Label, Dose-finding, Phase I/II Trial of Pentostatin in the Treatment of Steroid-refractory Acute Graft Versus Host Disease (aGvHD)
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 30, 2002
Completion date
November 3, 2005
Enrollment
36
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft versus host disease